HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Jacob Gurevitch Vladimir Yakirevich Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gurevitch, J. Articles by Yakirevich, V. Search for Related Content PubMed PubMed Citation Articles by Gurevitch, J. Articles by Yakirevich, V.

J Thorac Cardiovasc Surg 1994;108:109-118
© 1994 Mosby, Inc.

CARDIOPULMONARY BYPASS, MYOCARDIAL MANAGEMENT, AND SUPPORT TECHNIQUES

Aprotinin improves myocardial recovery after ischemia and reperfusion:Effects of the drug on isolated rat hearts

Tel-Aviv, Israel

From the Department of Thoracic and Cardiovascular Surgery, Tel- Aviv-Elias Sourasky Medical Center, Tel-Aviv University, Tel- Aviv, Israel.

Received for publication Dec. 12, 1992. Accepted for publication Sept. 27, 1993. Abstract

The effects of aprotinin, a protease inhibitor, on the ischemic and nonischemic isolated rat heart was investigated with the use of the modified Langendorff model. During phase I of the study, hearts were perfused with either low-dose aprotinin (10⁵KIU/L),high-dose aprotinin (10⁶KIU/L), or normal saline solution added to modified Krebs-Henseleit solution. No statistically significant differences in contraction amplitude, contractility, coronary flow, and wet/dry heart weight ratio were observed among the three groups of hearts. In phase II, hearts were exposed to a 40-minute period of global ischemia at 31° C. Ischemic arrest was induced by warm cardioplegia. Before ischemia and during cardioplegia, hearts were perfused with either aprotinin 10⁶KIU/L(n = 10) or normal saline solution (n = 10) for 30 minutes. On reperfusion, recovery of hearts treated with aprotinin was significantly better than that of control hearts, as reflected by better contractility (analysis of variance, p = 0.011), higher coronary flow (p < 0.025), and lower creatine kinase levels (p < 0.05). No statistically significant differences in contraction amplitude were observed between the two groups. When the effect of ischemia within each group of hearts was analyzed, the preserving effect of aprotinin was even more pronounced. In the control group, ischemia caused a decrease in contractility (p < 0.025) and a decrease in oxygen consumption (p = 0.006); by contrast, in the aprotinin group the preischemic values were maintained. Accordingly, we conclude that aprotinin at concentrations up to 10⁶KIU/L has no deleterious effect on normally perfused hearts and has a significant protective effect on the ischemic heart when used in high doses in the preischemic period. (J THORAC CARDIOVASC SURG 1994;108:109-18)

This article has been cited by other articles:

				M. P. Eaton Antifibrinolytic Therapy in Surgery for Congenital Heart Disease Anesth. Analg., April 1, 2008; 106(4): 1087 - 1100. [Abstract] [Full Text] [PDF]

				R. Poston and O. Toshinaga Reply Ann. Thorac. Surg., November 1, 2006; 82(5): 1951 - 1952. [Full Text] [PDF]

				T. A. Khan, C. Bianchi, P. Voisine, J. Feng, J. Baker, M. Hart, M. Takahashi, G. Stahl, and F. W. Sellke Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest J. Thorac. Cardiovasc. Surg., October 1, 2004; 128(4): 602 - 608. [Abstract] [Full Text] [PDF]

				M. Hendrikx, F. Rega, L. Jamaer, T. Valkenborgh, H. Gutermann, and U. Mees Na+/H+-exchange inhibition and aprotinin administration: promising tools for myocardial protection during minimally invasive CABG Eur. J. Cardiothorac. Surg., May 1, 2001; 19(5): 633 - 639. [Abstract] [Full Text] [PDF]

				A. Rahman, B. Ustunda, O. Burma, I. H. Ozercan, A. Cekirdekci, and M. K. Bayar Does aprotinin reduce lung reperfusion damage after cardiopulmonary bypass? Eur. J. Cardiothorac. Surg., November 1, 2000; 18(5): 583 - 588. [Abstract] [Full Text] [PDF]

				M. Hendrikx, H. Jiang, H. Gutermann, J. Toelsie, D. Renard, A. Briers, J. L. Pauwels, and U. Mees RELEASE OF CARDIAC TROPONIN I IN ANTEGRADE CRYSTALLOID VERSUS COLD BLOOD CARDIOPLEGIA J. Thorac. Cardiovasc. Surg., September 1, 1999; 118(3): 452 - 459. [Abstract] [Full Text] [PDF]

				C. F. Wippermann, F. X. Schmid, B. Eberle, R. G. Huth, C. Kampmann, D. Schranz, and H. Oelert Reduced inotropic support after aprotinin therapy during pediatric cardiac operations Ann. Thorac. Surg., January 1, 1999; 67(1): 173 - 176. [Abstract] [Full Text] [PDF]

				R. F. Roberts, G. P. Nishanian, J. N. Carey, S. H. Darbinian, J. D. Kim, Y. Sakamaki, J. Y. Chang, V. A. Starnes, and M. L. Barr Addition of aprotinin to organ preservation solutions decreases lung reperfusion injury Ann. Thorac. Surg., July 1, 1998; 66(1): 225 - 230. [Abstract] [Full Text] [PDF]

				G. Zund, A. L. Dzus, R. Pretre, U. Niederhauser, P. Vogt, and M. Turina Endothelial cell injury in cardiac surgery: salicylate may be protective by reducing expression of endothelial adhesion molecules Eur. J. Cardiothorac. Surg., March 1, 1998; 13(3): 293 - 297. [Abstract] [Full Text] [PDF]

				J. Gurevitch, D. Pevni, I. Frolkis, M. Matsa, Y. Paz, R. Mohr, and V. Yakirevich Captopril in Cardioplegia and Reperfusion: Protective Effects on the Ischemic Heart Ann. Thorac. Surg., March 1, 1997; 63(3): 627 - 633. [Abstract] [Full Text]